Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Licorice extract, in its BP EP USP Pharma Grade, represents a culmination of careful raw material selection and stringent processing standards set by pharmacopeias such as the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP). Sourced from Glycyrrhiza glabra roots, the extract emerges through a meticulous water-based extraction, yielding a potent, concentrated compound. Its role goes far beyond sweetening; it acts as a key active pharmaceutical ingredient, with recognized properties that support formulation needs across antitussives, demulcents, and even anti-inflammatory therapies.
Most who handle licorice extract notice its range of physical forms: a dark brown to near-black powder, semi-hard block, crystalline fragment, viscous liquid, or even small, glossy pearls. Each presentation traces back to customization for dosing, solubility, or manufacturing process. These forms keep licorice compatible with various mixing, blending, or granulation tools used in pharmaceutical production. The powder form, for instance, brings a density typically between 0.4 and 0.7 g/cm³, measured at 25°C. The creamy, semi-solid variant supports uniform melting and dispersal, especially in lozenge or tablet making. Material remains stable under cool, dry conditions, away from direct light—critical for retaining the glycyrrhizin content central to licorice’s bioactivity.
Pharma grade licorice extract keeps to strict identifiers. Molecular formula commonly reads as C42H62O16, referencing glycyrrhizin’s primary structure. Glycyrrhizin content often falls above 98%, supporting reliable pharmacological response and minimizing batch-to-batch variance. pH sits close to 5.0–6.5 for solid types and remains stable even in liquid solutions. Moisture content stays below 8%, preserving flow and discouraging microbial growth. Ash content rarely exceeds 8%, a sign of high purity and clean extraction. These measurements anchor licorice’s eligibility for therapeutic use; if purity dips or contaminants rise, the batch fails compliance. For traceability in regulatory systems, the global HS Code 13021200 tracks this product across economic borders.
Glycyrrhizin forms the heart of pharma-grade licorice, structured as a complex triterpenoid saponin. It supports both sweetness and physiological action by inhibiting 11β-hydroxysteroid dehydrogenase. This molecular effect extends into real-world uses—soothing respiratory discomfort, supporting localized inflammation relief, or masking bitterness in active tablet cores. Its crystalline and flake forms offer flexibility in pharmaceutical blending, where physical compatibility often determines process reliability. Liquid forms deliver quick solubility, helpful in syrup and oral rinse manufacture. Density, measured rigorously during quality tests, dictates compatibility with excipients as well as packaging stability.
Solid licorice extract, appearing as powder, flakes, pearls, or opaque blocks, carries advantages in portioning, volumetric dosing, and storage efficiency. Larger crystal or block formats help those scaling for industrial batches, while powders satisfy smaller lots and precision mixes. Liquid licorice extract keeps a viscous, almost syrupy state, with density often above 1.00 g/cm³. Each format supports tight pharmaceutical tolerances dictated by a product’s end-use. In shipping, flakes and crystals typically ship in moisture-tight polyethylene-lined drums, while liquids move in sealed food-grade containers, limiting oxidative and microbial risk.
Everything has a risk profile worth assessing, especially in active chemicals. Licorice extract, while safe at pharmaceutical concentrations, can lead to adverse outcomes if overused. Glycyrrhizin, in excess, interferes with potassium balance and may induce pseudoaldosteronism, marked by hypertension and fluid retention. Storage in dry, cool rooms not only maintains potency but also reduces chances of microbial spoilage. No major reactive hazards appear under routine handling, but respiratory masks and gloves often factor in, considering the fine dust generated from powders. Regulatory oversight by BP, EP, and USP standards keeps the thresholds for contaminants, heavy metals, and microbial load well below harmful levels. Shipping documentation always flags any unusual risk, especially for bulk or specialty customs, aligning with controlled material status.
Pharma-grade licorice always begins with certified Glycyrrhiza glabra roots, predominantly grown in temperate zones across Southern Europe, Central Asia, and the Middle East. Full traceability from field through extraction to final packaging not only satisfies regulatory audits but also underpins product reputation with end users—whether that’s a hospital, research lab, or multinational manufacturer. The journey from fresh roots to refined extract hangs on sustainable practices, clean water extraction, and modern filtration, which in turn serves commitments to transparency. Regular spectrometric scans, purity checks, and residual solvent analysis fill out dense certificates of analysis, pointing to robust oversight on every finished lot.
Reliable licorice extract isn’t simply about meeting a checklist; it touches quality of life, from gentle cough relief to complex immunomodulatory research. Patients who rely on these medications expect batch-to-batch consistency, free from unexpected side effects, adulterants, or loss of efficacy. From a personal perspective, attention to material detail matters—labs depend on it, as do final users who often never see or taste the active compound. Keeping a steady grip on technical specs, such as molecular formula and impurity data, stands as much for integrity as for regulatory box-checking. In this field, a lapse anywhere in the chain—be that harvest, extraction, or storage—can echo into tangible health risks.
Modern production of licorice extract BP EP USP Pharma Grade doesn’t stand still. Clean-label extraction using food-grade solvents and reduced environmental burden keeps drawing attention, especially from pharmaceutical buyers who value long-term supplier reliability. Automation in extraction decreases human error and speeds up both safety and compliance checks. Adopting tighter digital tracking for raw material origin and batch testing aims to close gaps still present in globalized supply networks. More robust collaborative research between growers, extractors, and pharmaceutical companies strengthens mutual accountability. Above all, ensuring open communication with end-users—about risks, best handling guides, and full specification transparency—carries the industry further into the future.
Chengguan District, Lanzhou, Gansu, China
